G1’s Cosela Approved for Treating Chemo-Induced Bone Marrow Suppression
The FDA approved G1 Therapeutics’ Cosela (trilaciclib) for reducing the frequency of chemotherapy-induced bone marrow suppression in adults with extensive-stage small cell lung cancer.
The drug, which is given by injection, is the first therapy in its class approved for reducing bone marrow suppression in adults being given certain types of chemotherapy for extensive-stage small cell lung cancer.
The approval was supported by clinical trials that demonstrated the drug significantly lowered the duration and severity of neutropenia in adults and decreased the occurrence of chemotherapy-induced bone marrow suppression. The treatment is expected to become available in early March.